Skip to main content
BVS logo

Bioventus Inc. (BVS) Stock Price & Analysis

Bioventus Inc. (BVS) — MoonshotScore 79/100 (Strong band), calculated Nov 18, 2026. Price $9.95 (-6.31%), as of the Nov 19, 2026 trading session; market cap $681M.

Educational signal · not a buy or sell recommendation · How to read this

$9.95 −$0.67 (-6.31%) Market Cap $681M

Bioventus Inc. · BVS · NASDAQ

Bioventus Inc. focuses on developing and commercializing clinical treatments that enhance the body's natural healing process. Their portfolio includes pain treatments, surgical solutions, and restorative therapies, serving physicians across various orthopedic specialties.

Price as of Nov 19, 2026

Key Statistics

79 of 100

MoonshotScore v2 · Bioventus (BVS)

Strong
Business Quality Elite (91)
Financial Safety Okay (44)
Valuation Fair (79)
Growth Durability Growing (61)
Momentum Rising (72)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality, though the balance sheet is only middling; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Fair; Growth Durability: Growing; Momentum: Rising.

  • EPS beat 1 of the last 4 reports
  • Altman Z 1.87 · Piotroski F 7
  • ROE 27.2% · ROA 8.5% · current ratio 1.68 · earnings yield 7.9% · free-cash-flow yield 11.6%

Helping: business quality, an attractive price, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for BVS (58 recorded, newest six shown)
RecordedScoreBand
83Exceptional
82Exceptional
82Exceptional
79Strong
79Strong
79Strong

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$9.95
Change on the day-6.31%
52-week range$6.47 – $15.89
Market capitalisation$681M—
Price / earnings (trailing)12.53
Shares traded on the day572.0K

Price & events

Other perspectives

Council score for Bioventus (BVS): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Neutral
Valuation Moderate
Growth Durability Moderate
Momentum Moderate

Legends Council

3 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Undervalued
Profit Margin Neutral
Debt/Equity Weak
ROE Strong
Gross Margin Strong

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 17, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Bioventus (BVS), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Bioventus Inc. (BVS) is listed on NASDAQ. It employs 960 people and is led by Robert Claypoole. The market values it at $681M.

2 · Latest results

What do the latest results show for Bioventus (BVS)?

Short answer · as of

Against analyst estimates the company has EPS beat 1 of the last 4 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$139M$3M$0.05 (diluted)
Q4 FY2025$158M$15M$0.21 (diluted)
Q1 FY2026$132M$3M$0.04 (diluted)
Q2 FY2026$153M$33M$0.47 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Bioventus (BVS)?

Short answer · as of

The MoonshotScore pillars rate business quality, an attractive price, positive momentum as strengths. The distress and quality screens read Altman Z 1.87 · Piotroski F 7. Trailing ratios: ROE 27.2% · ROA 8.5% · current ratio 1.68 · earnings yield 7.9% · free-cash-flow yield 11.6%.

4 · What to check next?

What should you watch next at Bioventus (BVS)?

Short answer · as of

The stored analyst-target capture is expired, so a current target watchpoint is unavailable.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Bioventus compare with its peers?

Short answer

Bioventus's score ranks tied for 7th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Delcath Systems, Inc. (DCTH) Same industry, near in market value$19.24 Nov 19, 2026$669M94 5-pillar Nov 18, 2026
IRadimed Corporation (IRMD) Same industry, near in market value$81.26 Nov 19, 2026$1.04B94 5-pillar Nov 18, 2026
InMode Ltd. (INMD) Same industry, near in market value$12.70 Nov 19, 2026$731M92 5-pillar Nov 18, 2026
Tactile Systems Technology, Inc. (TCMD) Same industry, near in market value$25.99 Nov 19, 2026$582M90 5-pillar Nov 18, 2026
BrainsWay Ltd. (BWAY) Same industry, near in market value$8.73 Nov 19, 2026$351M87 5-pillar Nov 18, 2026
Johnson & Johnson (JNJ) Named competitor$267.14 Nov 19, 2026$643B83 5-pillar Nov 18, 2026
Bioventus (BVS) — this page$9.95$681M79
Zimmer Biomet Holdings, Inc. (ZBH) Named competitor$101.47 Nov 19, 2026$19.2B79 5-pillar Nov 18, 2026
Integra LifeSciences Holdings Corporation (IART) Same industry, near in market value$13.55 Nov 19, 2026$1.05B68 5-pillar Nov 18, 2026
Varex Imaging Corporation (VREX) Same industry, near in market value$18.14 Nov 19, 2026$770M62 5-pillar Nov 18, 2026
SI-BONE, Inc. (SIBN) Same industry, near in market value$23.75 Nov 19, 2026$1.07B39 5-pillar Nov 18, 2026
OrthoPediatrics Corp. (KIDS) Same industry, near in market value$32.51 Nov 19, 2026$849M37 5-pillar Nov 18, 2026
908 Devices Inc. (MASS) Same industry, near in market value$9.37 Nov 19, 2026$390M35 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Last captured analyst target range, low to high (expired, captured Nov 18, 2026)
$18.00 – $19.00
Last captured analyst target (expired, captured Nov 18, 2026)
$18.33
Last captured median analyst target (expired, captured Nov 18, 2026)
$18.00

Historical target record · Captured · Capture expired; not a current watchpoint.

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Jun 3, 2026

Transactions
30
Identified insiders
10
Purchases
0
Sales
0
Other transactions
30

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held BVS in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported BVS in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Bioventus (BVS)?

Read these with our analysis →

What Investors Ask About Bioventus (BVS)

These answers are editorial: 1 of these 9 answers is drawn from the BVS research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for BVS?

BVS carries the MoonshotScore stated above — the Strong band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Bioventus Inc. focuses on developing and commercializing clinical treatments that enhance the body's natural healing process.

Is BVS a good stock to buy?

Stock Expert AI does not rate BVS buy, sell or hold. Bioventus Inc. carries a MoonshotScore, in the Strong band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the BVS stock price today?

The last price recorded for Bioventus Inc. (BVS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the BVS price target?

The last analyst consensus price target we captured for Bioventus Inc. (BVS), with its FMP capture date, is listed under Analyst targets & estimates on this page. That capture has expired, so read it as historical, not as a current target. Targets are analyst opinions, not a Stock Expert AI forecast.

What are the main risks for BVS?

Bioventus Inc. faces several risks inherent to the medical device industry. One significant risk is competition from larger, more established companies with greater resources and broader product portfolios.

What are the key factors to evaluate for BVS?

Bioventus Inc. (BVS) holds a MoonshotScore in the high range. To weigh it, start with the trailing P/E under Price & valuation on this page. Not financial advice.

How frequently does BVS data refresh on this page?

BVS's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven BVS's recent stock price performance?

Bioventus Inc. (BVS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product portfolio focused on natural healing. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider BVS overvalued or undervalued right now?

The trailing P/E of Bioventus Inc. (BVS) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 17 figures on this page — 10 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.